Oncothyreon (ONTY)
Oncothyreon Market Cap: 157.87M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ONTY Market Cap Rankings
| Overall | 30th percentile | 3262 of 4664 |
| Sector | 40th percentile | 315 of 527 in Healthcare |
| Industry | 46th percentile | 87 of 164 in Biotechnology |
ONTY Market Cap Range, Past 5 Years
| Minimum | 15.59M | Dec 2008 |
| Maximum | 382.30M | Jun 2011 |
| Average | 124.81M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these ONTY related companies
ONTY News
Oncothyreon Initiates Phase 1/2 Trial of PX-866 in Combination with Vemurafenib
May 31, 4:03PM Benzinga
May 31, 4:03PM Benzinga
$ONTY to Present at Jefferies 2012 Global Healthcare Conference on Tue, June 5 at 4 pm ET. Webcast at http://stks.co/42IS
about a day ago by abubnic
about a day ago by abubnic
RT @abubnic $ONTY was up this week on this news of stimuvax early studies w breast cancer: http://stks.co/3zoi
about 6 days ago by js_thorne
about 6 days ago by js_thorne
$ONTY was up this week on this news of stimuvax early studies w breast cancer: http://stks.co/3zUk
about 6 days ago by abubnic
about 6 days ago by abubnic
$ONTY stimuvax trials are still ongoing... these prices are sick. Still not holding a position though
about 9 days ago by js_thorne
about 9 days ago by js_thorne
@yarrr $ONTY... I see no spike at all. Just returning to where it was a few days ago.
about 9 days ago by mitrado
about 9 days ago by mitrado
$ONTY looking at this... what's the next hurdle for this drug and timeline?
about 9 days ago by selectstock
about 9 days ago by selectstock
The fact that the ASCO PX-866 early data failed to impress was a gift. Think *stimuvax* when loading up at these bargain prices for $ONTY.
about 10 days ago by abubnic
about 10 days ago by abubnic
Wished I was in $ONTY at $3.50 last year but didn't get in until $6. Come Dec/Jan, you'll be VERY happy to have scooped it up @ this price.
about 10 days ago by abubnic
about 10 days ago by abubnic
@adamfeuerstein ur thots on future prospects of $ONTY imo would be shut down by now if trials werent promising but stock not reflecting
about 10 days ago by hml5bcp
about 10 days ago by hml5bcp
@GArgondizza @taketheplunge Bought some more at that price as well. $ONTY
about 10 days ago by PattyA_F
about 10 days ago by PattyA_F
@GArgondizza Good for you. I bought $onty calls out to jan 13 to hedge my shares rather than av dn. Agree it comes back late 12 early 13
about 10 days ago by taketheplunge
about 10 days ago by taketheplunge
$ONTY Mentioned more than normal on StockTwits - Currently at 2 x average daily social activity
about 13 days ago by TradeIdeasQuant
about 13 days ago by TradeIdeasQuant
@GArgondizza If I can get $ONTY @ $3.50, this is my big purchase to carry me through Dec/Jan.
about 13 days ago by abubnic
about 13 days ago by abubnic
Endocyte and Oncothyreon Look to Benefit From Enhancements to U.S. Patent System
May 15, 8:20AM Marketwire
May 15, 8:20AM Marketwire
Oncothyreon to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 8:00AM PR Newswire
May 10, 8:00AM PR Newswire
Oncothyreon Announces First Quarter 2012 Financial Results Conference Call
Apr 30, 8:00AM PR Newswire
Apr 30, 8:00AM PR Newswire
Oncothyreon to Present at Future Leaders in the Biotech Industry Conference
Apr 13, 8:00AM PR Newswire
Apr 13, 8:00AM PR Newswire
Oncothyreon Prices $47.0 Million Public Offering of Common Stock at $4.00 per Share
Mar 29, 9:16AM Benzinga
Mar 29, 9:16AM Benzinga
Oncothyreon Initiates Phase 1 Trial of Therapeutic Vaccine Product Candidate ONT-10
Mar 14, 8:01AM Benzinga
Mar 14, 8:01AM Benzinga
Cantor Fitzgerald Maintains Buy on Oncothyreon; Phase III Start Trial Continues to Endpoint
Mar 06, 10:10AM Benzinga
Mar 06, 10:10AM Benzinga
Oncothyreon (ONTY) Posts Wider than Expected Q4 Loss of 27c; Guides FY12 Expenses
Mar 06, 8:06AM Street Insider
Mar 06, 8:06AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ONTY | 3.62 | +0.00 | +0.00% | 157.87M |
| ONSM | 0.5797 | -0.00 | -0.05% | 7.009M |
| ONP | 1.93 | -0.13 | -6.31% | 38.03M |
| ONNN | 6.76 | +0.00 | +0.00% | 3.056B |
| ONFC | 10.06 | +0.13 | +1.31% | 69.51M |
| ONEQ | 111.73 | -0.43 | -0.38% | |
| ONE | 12.75 | -1.43 | -10.08% | 805.57M |
| ONCY | 3.40 | -0.07 | -2.02% | 265.18M |
| ONB | 11.59 | +0.03 | +0.26% | 1.092B |
| OMX | 4.88 | +0.10 | +2.09% | 413.80M |